Proactive Investors - Run By Investors For Investors

Silence Therapeutics confirms Dr Rob Quinn as chief financial officer

"I'm very pleased that Rob will serve as full-time chief financial officer and on behalf of the board I would like to formally welcome him to this role," said David Horn Solomon, Silence's CEO
Board room
Dr Quinn is a chartered accountant and qualified at Deloitte

Silence Therapeutics PLC (LON:SLN) has given interim chief financial officer (CFO) Rob Quinn the job on a permanent basis.

Quinn has been the interim CFO since January 2019, having been the head of Financial Planning and Analysis at the company for the two years prior to getting the CFO gig.

READ Silence Therapeutics makes key new hire

“Rob's scientific and financial skills, alongside his commercial acumen make him an asset to the Silence team. During his time at the company he has continued to play an important role in building the business, with a keen appreciation for how we will grow in the future," said David Horn Solomon, the chief executive officer of the AIM-listed drugs developer.

 

View full SLN profile View Profile

Silence Therapeutics PLC Timeline

Related Articles

antibodies
May 02 2019
Avacta is using Affimers to develop its own cancer therapy, but it also licenses the technology to other companies, including major pharma group ModernaTX and LG Chem Life Sciences
salmon
June 24 2019
Long-term fundamentals remain firmly in the seafood specialist's favour
Cameron Durrant
March 04 2019
A goal is to improve the safety of CAR-T therapies, used in the treatment of children with acute lymphoblastic leukemia and adults with advanced lymphomas

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use